Skip to main navigation
Skip to search
Skip to main content
Research Profiles at Washington University School of Medicine Home
Help & FAQ
Home
Profiles
Departments, Divisions and Centers
Research output
Search by expertise, name or affiliation
Combination therapy of dyslipidemia
Anne Carol Goldberg
Institute of Clinical and Translational Sciences (ICTS)
Division of Endocrinology, Metabolism & Lipid Research
Research output
:
Contribution to journal
›
Review article
›
peer-review
8
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Combination therapy of dyslipidemia'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Dyslipidemia
100%
Statins
100%
Combination Therapy
100%
Clinical Trials
66%
High-density Lipoprotein Cholesterol (HDL-C)
66%
Lipoprotein Levels
66%
Low-density Lipoprotein Cholesterol (LDL-C)
33%
Low-density Lipoprotein
33%
Clinical Practice Guidelines
33%
Additive Effect
33%
Drug Class
33%
New Drugs
33%
Triglyceride Level
33%
Substantial Reduction
33%
Lifestyle Modification
33%
Current Guidelines
33%
Fibrates
33%
Lipid Levels
33%
Atherosclerotic Vascular Disease
33%
Atherosclerotic Cardiovascular Disease (ASCVD)
33%
Lipid-lowering Therapy
33%
Cholesterol Reduction
33%
Niacin
33%
Lipid-modifying Drugs
33%
Pharmacology, Toxicology and Pharmaceutical Science
Dyslipidemia
100%
Combination Therapy
100%
Clinical Trial
66%
Statin (Protein)
66%
High Density Lipoprotein
33%
Lipoprotein
33%
Triacylglycerol
33%
Vascular Disease
33%
Low Density Lipoprotein
33%
High Density Lipoprotein Cholesterol
33%
Low Density Lipoprotein Cholesterol
33%
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
33%
Coronary Artery Atherosclerosis
33%
Fibric Acid Derivative
33%
Nicotinic Acid
33%
Lipid Modifying Drug
33%
Nursing and Health Professions
Combination Therapy
100%
Dyslipidemia
100%
Statin (Protein)
66%
Practice Guideline
33%
High Density Lipoprotein Cholesterol
33%
Low Density Lipoprotein Cholesterol
33%
Lipoprotein
33%
Clinical Guideline
33%
Lifestyle Modification
33%
Fibric Acid Derivative
33%
Triacylglycerol Level
33%
Vascular Disease
33%
Nicotinic Acid
33%
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
33%
Coronary Artery Atherosclerosis
33%
High Density Lipoprotein
33%
Low Density Lipoprotein
33%